Are you Dr. Doyle?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 40 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
22 S Greene St
Baltimore, MD 21201Phone+1 410-328-5793Fax+1 410-328-0248
Summary
- Dr. Laurence Doyle, MD is an oncologist in Baltimore, Maryland. He is currently licensed to practice medicine in Maryland.
Education & Training
- University of MarylandResidency, Internal Medicine, 1978 - 1981
- University of Maryland School of MedicineClass of 1978
Certifications & Licensure
- MD State Medical License 1979 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 49 citationsEffect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.Kevin Kalinsky, Fangxin Hong, Carolyn K. McCourt, Jasgit C. Sachdev, Edith P. Mitchell
JAMA Oncology. 2021-02-01 - 97 citationsBiomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.Khanh T. Do, Giovanna Speranza, Rachel Bishop, Sonny Khin, Larry Rubinstein
Investigational New Drugs. 2015-02-01 - 121 citationsBerzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.Panagiotis A. Konstantinopoulos, Su Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer
The Lancet. Oncology. 2020-06-15